


## JAK3-IN-9

## Chemical Properties

|                   |   |
|-------------------|---|
| CAS No. :         | 1430095-30-9  |
| Formula:          | C <sub>17</sub> H <sub>23</sub> N <sub>5</sub> O <sub>4</sub> S   |
| Molecular Weight: | 393.46  |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br>Actual storage temperature shall be subject to the COA. |



## Biological Description

|               |   |
|---------------|---|
| Description   | JAK3-IN-9 is a potent and orally active inhibitor of the Janus kinase 3 (JAK3) enzyme, displaying an impressive IC <sub>50</sub> value of 1.7 nM. It exhibits high selectivity towards the JAK3 signaling pathway, making it a valuable tool for studying autoimmune diseases. Additionally, JAK3-IN-9 possesses desirable characteristics such as low toxicity and excellent oral bioavailability. It also demonstrates promising anti-arthritis activity, thus enhancing its potential as a therapeutic agent [1].  |
| Targets(IC50) | Others,JAK  |
| In vitro      | JAK3-IN-9 (compound 11i) selectively inhibits JAK3 with an IC <sub>50</sub> of 1.7 nM [1]. In Cell Viability Assays using PBMCs at 1 μM concentration and 30-minute incubation, it shows preferential inhibition of JAK3 [1].   |
| In vivo       | JAK3-IN-9, referred to as compound 11i, demonstrated selective inhibition of JAK3 cytokine signaling in primary cells when administered orally at dosages of 3, 10, and 30 mg/kg to female Lewis rats once daily for 20 days. Additionally, it exhibited a high area under the curve (AUC) of 2104 μg/ml, increased the half-life to 2.56 hours, and showed favorable oral bioavailability of 48% upon a single intravenous injection at 1 mg/kg in male DBA1j mice aged 8 to 12 weeks. Furthermore, JAK3-IN-9 significantly reduced paw swelling in a dose-dependent manner, with an effective dose (ED <sub>50</sub> ) value of 10 mg/kg, after oral administration once daily for 20 days at a dose of 30 mg/kg. These results, obtained from studies conducted on male DBA1j mice and female Lewis rats, indicate its potential as an anti-arthritis agent in the CIA mice model. |

### Preparing Stock Solutions

---

|       | <b>1mg</b> | <b>5mg</b> | <b>10mg</b> |
|-------|------------|------------|-------------|
| 1 mM  | 2.5416 mL  | 12.7078 mL | 25.4155 mL  |
| 5 mM  | 0.5083 mL  | 2.5416 mL  | 5.0831 mL   |
| 10 mM | 0.2542 mL  | 1.2708 mL  | 2.5416 mL   |
| 50 mM | 0.0508 mL  | 0.2542 mL  | 0.5083 mL   |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481